Medical Oncology Lab, Department of Molecular Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.
The Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland.
Breast Cancer Res Treat. 2024 Oct;207(3):471-476. doi: 10.1007/s10549-024-07431-6. Epub 2024 Aug 1.
Receptor and subtype discordance between primary breast tumours and metastases is a frequently reported phenomenon. The aim of this article is to review the current evidence on receptor discordance in metastatic breast cancer and to explore the benefit of performing a repeat biopsy in this context.
Searches were undertaken on PubMed and Clinicaltrials.gov for relevant publications and trials.
The current guidelines recommend offering to perform a biopsy of a metastatic lesion to evaluate receptor status. The choice of systemic therapy in metastatic disease is often based on the receptor status of the primary lesion. As therapeutic decision making is guided by subtype, biopsy of the metastatic lesion to determine receptor status may alter treatment. This article discusses discordance rates, the mechanisms of receptor discordance, the effect of discordance on treatment and survival outcomes, as well as highlighting some ongoing clinical trials in patients with metastatic breast cancer.
原发性乳腺癌和转移灶之间受体和亚型不一致是一种经常报道的现象。本文的目的是综述转移性乳腺癌中受体不一致的现有证据，并探讨在这种情况下重复进行活检的益处。
在 PubMed 和 Clinicaltrials.gov 上进行了相关文献和试验的检索。
目前的指南建议对转移灶进行活检以评估受体状态。转移性疾病的系统治疗选择通常基于原发性病变的受体状态。由于治疗决策是基于亚型的，因此对转移灶进行活检以确定受体状态可能会改变治疗方法。本文讨论了不一致率、受体不一致的机制、不一致对治疗和生存结果的影响，并强调了一些正在进行的转移性乳腺癌患者的临床试验。
